Somewhat Positive Media Coverage Somewhat Unlikely to Impact Depomed (DEPO) Share Price
Media stories about Depomed (NASDAQ:DEPO) have been trending somewhat positive on Friday, Accern reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Depomed earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news coverage about the specialty pharmaceutical company an impact score of 45.6162431985821 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Depomed : to Participate at the Annual Piper Jaffray Healthcare Conference (4-traders.com)
- Monster Beverage Corporation, (NASDAQ: MNST), Depomed, Inc., (NASDAQ: DEPO), Alcoa Corporation, (NYSE: AA … – Stocks In The News (press release) (tradingnewsnow.com)
- Depomed to Participate at the Annual Piper Jaffray Healthcare Conference (finance.yahoo.com)
- Brokerages Anticipate Depomed, Inc. (DEPO) Will Announce Quarterly Sales of $92.77 Million (americanbankingnews.com)
- Depomed, Inc. (NASDAQ: DEPO) – Attention Seeking Stock – Alpha Beta Stock (alphabetastock.com)
Depomed (DEPO) opened at $6.30 on Friday. Depomed has a 1 year low of $4.31 and a 1 year high of $21.38. The company has a quick ratio of 0.79, a current ratio of 0.83 and a debt-to-equity ratio of 2.90.
Several equities analysts recently issued reports on the company. Morgan Stanley lowered Depomed from an “equal weight” rating to an “underweight” rating and reduced their price target for the stock from $12.00 to $5.00 in a research report on Tuesday, August 8th. Royal Bank Of Canada set a $10.00 price target on Depomed and gave the stock a “hold” rating in a research report on Friday, October 20th. Piper Jaffray Companies restated a “hold” rating and set a $9.00 price target on shares of Depomed in a research report on Sunday, September 10th. UBS Group AG raised their price target on Depomed from $6.00 to $7.00 and gave the stock a “neutral” rating in a research report on Friday, November 10th. Finally, Janney Montgomery Scott lowered Depomed from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $18.00 to $8.00 in a research report on Tuesday, August 8th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $10.64.
Depomed Company Profile
Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).
Receive News & Stock Ratings for Depomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed Inc. and related stocks with our FREE daily email newsletter.